Bristol-Myers Squibb (BMY) Revenue — Quarter Ended Sep 30, 2024
Revenue for the quarter declined compared to the immediately preceding period. However, it rose relative to the same period a year earlier.
Key takeaway
Quarter ended Sep 30, 2024 · FY2024 Q3
Revenue for the quarter declined compared to the immediately preceding period. However, it rose relative to the same period a year earlier.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$11.9B
Revenue reported for this quarter.
Quarter-over-quarter
-2.5%
Change from the immediately preceding quarter.
Year-over-year
+8.4%
Change from the comparable year-ago quarter.
Trailing four quarters
$47.4B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Dec 31, 2023 | $11.5B | +0.6% |
| Mar 31, 2024 | $11.9B | +4.7% |
| Jun 30, 2024 | $12.2B | +8.7% |
| Sep 30, 2024 | $11.9B | +8.4% |
Revenue performance
The reported revenue was lower than the prior quarter, reflecting a sequential decrease. Compared with the same quarter one year ago, revenue increased.
Quarterly comparison
Over the trailing twelve months, revenue remained above the level of the prior year's comparable period. The sequential decline followed a period of growth in the earlier quarters of the year.
What to watch
The sequential revenue decline may warrant monitoring given the prior upward trend.